GlaxoSmithKline | USA

Dr. Kendall Frazier is a director of pathology and senior science fellow at GlaxoSmithKline where he has been for 16 years. His primary duties at GSK involve acting as a toxicologic study pathologist and as a scientific consultant for drug development projects, and he is a member of the Nephrology Safety Panel. Current scientific interests involve mechanisms of drug-induced toxic responses in the urinary system. 

He holds a BSc in biology from Wichita State University, a DVM from Kansas State College of Veterinary Medicine and a PhD in molecular biology from the University of Miami, all in the United States. He completed a residency in comparative pathology at University of Miami's School of Medicine and is board certified in both Pathology and Toxicology. Dr. Frazier has previously held faculty appointments at the University of Miami and at the University of Georgia, School of Veterinary Medicine. 

His focus in academia was on rodent models of kidney failure and mechanisms of toxic and infectious renal disease.  He has authored over 75 scientific journal publications and book chapters.  He chaired the Urinary System subcommittee for the Society of Toxicologic Pathology's (STP) INHAND initiative, and has chaired many other committees and meetings for the STP, the American College of Veterinary Pathologists (ACVP) and other organizations such as the American College of Toxicology and World Pharma Congress. He has been on the editorial board for multiple scientific journals, and has also been honored as a fellow of the International Academy of Toxicologic Pathology. In 2015, he spent 6 months on a PULSE assignment working in Ghana (Africa) with the Tropical Laboratory Initiative of the Millennium Villages Project.